SOPHIA ANTIPOLIS, France, November 20 /PRNewswire/ -- With the recent FDA approval of LMS-Lung/Track and LMS-Liver, two applications dedicated to the evaluation and follow-up of cancerous or other potentially malignant lesions identified in chest and liver CT images, MEDIAN Technologies succeeds in setting the trend in diagnostic oncology imaging. The company will showcase its complete portfolio of Lesion Management Solutions at the 93rd annual meeting of the Radiological Society of North America (RSNA) in Chicago, hall B, booth #8548.
LMS-Lung/Track and LMS-Liver are designed to efficiently assist the radiologists in all steps from lesion measurement and follow-up to report generation for the referring physicians. The applications segment user-identified lesions and measure their key characteristics such as volume and longest axial diameters. They also pair the lesions in follow-up exams, compute their growth and doubling time and finally generate reports according to the RECIST criteria used in oncology to assess the response to treatment of solid tumors. LMS-Lung/Track and LMS-Liver thus perform automatically all the tedious tasks the radiologists would normally carry out manually. This contributes to improving the workflow and reducing intra and inter-observer variability.
"Diagnostic oncology imaging is all about evaluating and following cancerous and suspicious lesions, such as pulmonary nodules," explained Fredrik Brag, CEO of MEDIAN Technologies. "MEDIAN Technologies is a specialized company focusing on delivering high-end solutions for all radiologists to accurately perform such evaluation and transmit the oncologists and other referring physicians the exact information they need in a record time. In brief, we can say that we work for the clinicians, so that they can provide the best possible patient care."
LMS-Lung/Track and LMS-Liver support images acquired on any multi-slice CT scanner, and can be integrated with modality or PACS/RIS workstations. "Integrating advanced clinical applications with PACS or RIS workstations is key in diagnostic oncology imaging. It guarantees access to the patients' previous exams necessary to perform follow-up studies and allows an immediate report transmission to the oncologists," said Gerard Milhiet, COO of MEDIAN Technologies. "We are proud to contribute to this breakthrough by bringing our applications right to the clinicians' desktops instead of having them move to dedicated workstations."
MEDIAN Technologies is currently deploying its LMS applications in 15 countries across Europe and expects to do the same in the US in the coming months, with the recent extension of its American sales force.
About MEDIAN Technologies
MEDIAN Technologies develops and sells advanced clinical applications for diagnostic oncology imaging. The company's product line, MEDIAN LMS - Lesion Management Solutions - is a comprehensive portfolio of clinical applications for the management of cancerous or other potentially malignant lesions diagnosed in chest and abdominal CT scans. LMS applications feature LMS-Liver, LMS-Lung/Track, LMS-Lung(*) and LMS-Colon*.
For further information please check MEDIAN Technologies website: http://www.mediantechnologies.com.
(*) Not FDA approved
Contact: Raphaelle Imbernon
Company: MEDIAN Technologies
Address: 120 rue Albert Caquot, 06410 Biot, France
|SOURCE MEDIAN Technologies|
Copyright©2007 PR Newswire.
All rights reserved